PRESS-NEWS.org - Press Release Distribution
PRESS RELEASES DISTRIBUTION

Forging a novel therapeutic path for patients with Rett Syndrome using AI

AI-enabled drug discovery approach identified potentially game-changing treatment which has been advanced from the lab bench to an FDA Orphan Drug Designation in record time

2025-07-02
(Press-News.org)

Forging a novel therapeutic path for patients with Rett Syndrome using AI

AI-enabled drug discovery approach identified potentially game-changing treatment which has been advanced from the lab bench to an FDA Orphan Drug Designation in record time

By Benjamin Boettner

(BOSTON) — Rett syndrome is a devastating rare genetic childhood disorder primarily affecting girls. Merely 1 out of 10,000 girls are born with it and much fewer boys. It is caused by mutations in the MeCP2 gene on the X chromosome, leading to a spectrum of cognitive and physical impairments, including repetitive hand motions, speech difficulties, and seizures. 

However, besides severe impairment of neurological functions, which has been the primary focus of researchers, Rett syndrome also upsets the functions of many non-neurological organs, including the digestive, musculoskeletal, and immune systems. This complexity has made the development of an effective cure able to treat the disease across the multiple tissues an extreme challenge.

Now, a highly multi-disciplinary research team at the Wyss Institute at Harvard University has made a significant breakthrough by leveraging an AI-driven drug discovery process in combination with innovative disease modeling. Their study identified a drug known as vorinostat as a promising treatment for Rett syndrome, demonstrating disease-modifying abilities across multiple neuronal and non-neuronal tissues in preclinical models of Rett syndrome that were superior to trofinetide, the only approved treatment for Rett syndrome. The findings are published in Communications Medicine.

Because vorinostat has already been approved by the Food and Drug Administration (FDA) to treat a blood disease, the Wyss-enabled startup Unravel Biosciences has been able to rapidly repurpose this drug as a therapy for Rett syndrome. Unravel Biosciences’ lead pipeline asset, RVL-001, is a proprietary formulation of vorinostat, which recently received an Orphan Drug Designation from the FDA. Unravel will be initiating a proof-of-concept clinical trial to assess the drug’s efficacy and safety in 15 female patients with Rett syndrome in Colombia later this year, and will test an “n-of-1 trial design” to evaluate different vorinostat treatments within individual patients, which is more appropriate to the complexity of the disease, and to rare disease communities in general.

“The identification and further development of vorinostat as the potentially first curative treatment for Rett syndrome would not have been possible without our unique AI-enabled computational approach to drug discovery, and its combination with an innovative disease model that broadly mimics the features of Rett syndrome,” said senior author and Wyss Founding Director Donald Ingber, M.D., Ph.D. “This new target-agnostic approach for drug discovery proved to be extremely fast and effective and, together with our unique technology translation capabilities, creates a model for us to tackle other diseases with unmet need that pose similarly enormous challenges.” Ingber is also the Judah Folkman Professor of Vascular Biology at Harvard Medical School and Boston Children’s Hospital, and the Hansjörg Wyss Professor of Biologically Inspired Engineering at Harvard John A. Paulson School of Engineering and Applied Sciences.

A new paradigm for drug discovery

Key to the discovery of vorinostat as a potential Rett syndrome therapy was the Wyss Institute’s computational nemoCAD pipeline that enabled the team to predict drug candidates not based on a specific target molecule of the disease – as most traditional drug discovery approaches do – but on changes that occur in the entire gene network across multiple organ systems in Rett syndrome. Richard Novak, Ph.D., then a Staff Scientist on Ingber’s team at the Wyss Institute and now CEO of Unravel and other members of the team originally developed nemoCAD as part of the Wyss-led DARPA THoR Project to be able to identify why some patients are more tolerant to infection with pathogens than others. This DARPA-funded project led the path to other successful demonstrations of drug discovery by the Wyss Institute across diverse medical challenges, from neuropsychiatry to artificial hibernation.

As a starting point to develop a treatment for the full clinical spectrum of symptoms experienced by Rett disease patients, the team created a small animal model consisting of tadpoles from the frog Xenopus laevis, in which they used CRISPR genome-engineering technology to generate various mutations inactivating the MeCP2 gene to reflect the diverse patient population. The engineered tadpoles recapitulated a range of critical features of Rett syndrome, including developmental and behavioral delay, seizures, as well as intestinal, muscle and brain anomalies. Importantly, the researchers could analyze this new Rett model for changes in gene expression, across multiple organs that are associated with Rett syndrome-specific neurological and non-neurological changes in behavior and tissue function.

The researchers then used nemoCAD to compare all gene expression changes that occurred in MeCP2-defective tadpoles vs. healthy tadpoles to predict drug compounds from a public data base curated by the NIH that could reverse the pathological changes in the same gene expression networks. LINCS, as the data base is called, contains gene expression signatures induced by more than 19,800 drug compounds in a large variety of human cell lines, including drugs that already have been approved by the FDA for the treatment of other diseases. This type of analysis far exceeds traditional gene expression analysis, which determines the expression changes of individual genes or smaller groups of genes in isolation from all other changes.

“Critically ill patients demand accelerated discovery of new treatment options for their understudied disorders. Computing how entire gene expression networks are changing in a concerted fashion allowed us to predict which drugs are the most likely to push the Rett-specific gene expression network back to its normal state across multiple organs,” said co-first author Novak, who led the project together with co-author and Unravel co-founder Frederic Vigneault, Ph.D. “We then went from a list of candidates predicted in silicoto directly validating the top candidates in vivo in our tadpole model within a few weeks, demonstrating an efficient way of identifying previously unknown therapeutic mechanisms,” Novak added.

Vorinostat scored the highest on the list and produced the strongest therapeutic effects in the genetically engineered tadpoles, which showed an impressive reversal of their disease features on a whole organism level. Symptoms such as seizures, unusual swimming motions that resemble repetitive behaviors in patients with Rett syndrome, as well as gastrointestinal and muscular symptoms were all potently suppressed by the drug; and vorinostat was much more effective at suppressing these symptoms than trofinetide. 

“Important for its translation toward patients, vorinostat also consistently reversed multiple symptoms of Rett syndrome in a preclinical mouse model, even when administered after symptoms were already in full progression, which trofinetide was unable to do. The FDA has considered success in this model as a critical milestone before deciding moving trofinetide to human clinical trials in the past,” said Tiffany Lin, a co-first author on the new study and Wyss Staff Scientist who worked closely with Novak and Vigneault in Ingber’s team. “Excitingly, with some additional formulation work, vorinostat produced significant therapeutic outcomes even as an oral treatment.”

New drug, new insights

Through their gene network predictions and in-depth analysis of the molecular and cellular processes affected in MeCP2-defective tadpoles and following treatment with vorinostat, the researchers discovered what could be an unexpected driving force of the disease. MeCP2 encodes a protein that regulates the expression of hundreds of genes. It does so by binding to DNA regions that carry so-called methyl groups, and forming complexes with other proteins. One such class of proteins is known as histone deacetylases (HDAC), which modify other proteins by removing a different small chemical group known as an acetyl group from them. The acetylation status of proteins such as histones and other proteins is misregulated in Rett syndrome due to the inactivation of MeCP2.

However, the team’s study in whole organisms utterly redefined this view. They found that while histones in the Rett syndrome models indeed were under-acetylated in brain cells, they, surprisingly, were over-acetylated in other tissues affected by the disease, like the gastrointestinal (GI) tract. Importantly, the team’s network analysis predicted vorinostat to also affect the acetylation of a-tubulin, a protein that plays important roles in neurodegenerative disorders and other diseases. a-tubulin assembles diverse cytoskeletal structures in cells that critically contribute to their functions, such as surface cilia that help move mucus in the lung and GI tract.

“In our models, a-tubulin in cilia was also hypo-acetylated in brain tissue but hyper-acetylated in the other tissues such as the GI tract, which correlated with signs of functional abnormalities, including inflammation,” said Lin. “Vorinostat was able to reverse this dysregulated a-tubulin acetylation pattern in both directions, which tells us that it must have targets beyond the HDAC family for which it is known, and that Rett syndrome, across multiple organs, is caused by mechanisms that should be explored further.” 

Unravel Biosciences, which was founded by Novak and Vigneault, together with Ingber and Wyss Institute Associate Faculty member Michael Levin, Ph.D., another author of the new study, is building on vorinostat and the team’s discovery of a new therapeutic mechanism to advance the possibly first curative therapy for Rett syndrome in a first patient cohort. “We are extremely excited to be reaching clinical stages following this rapid discovery and development journey and hope to be able to impact the lives of Rett syndrome patients in an unprecedented way,” said Novak.

The study was also authored by Shruti Kaushal, Megan Sperry, Erica Gardner, Sahil Loomba, Kostyantyn Shcherbina, Vishal Keshari, Alexandre Dinis, Anish Vasan, Vasanth Chandrasekhar, Takako Takeda, Rahul Nihalani, Sevgi Umur, and Jerrold Turner.

PRESS CONTACTS

Wyss Institute for Biologically Inspired Engineering at Harvard University
Benjamin Boettner, benjamin.boettner@wyss.harvard.edu

###

The Wyss Institute for Biologically Inspired Engineering at Harvard University (www.wyss.harvard.edu) is a research and development engine for disruptive innovation powered by biologically-inspired engineering with visionary people at its heart. Our mission is to transform healthcare and the environment by developing ground-breaking technologies that emulate the way Nature builds and accelerate their translation into commercial products through formation of startups and corporate partnerships to bring about positive near-term impact in the world. We accomplish this by breaking down the traditional silos of academia and barriers with industry, enabling our world-leading faculty to collaborate creatively across our focus areas of diagnostics, therapeutics, medtech, and sustainability. Our consortium partners encompass the leading academic institutions and hospitals in the Boston area and throughout the world, including Harvard’s Schools of Medicine, Engineering, Arts & Sciences and Design, Beth Israel Deaconess Medical Center, Brigham and Women’s Hospital, Boston Children’s Hospital, Dana–Farber Cancer Institute, Massachusetts General Hospital, the University of Massachusetts Medical School, Spaulding Rehabilitation Hospital, Boston University, Tufts University, Charité – Universitätsmedizin Berlin, University of Zürich, and Massachusetts Institute of Technology.

 

END



ELSE PRESS RELEASES FROM THIS DATE:

Global drought hotspots report catalogs severe suffering, economic damage in 2023-2025

2025-07-02
Fuelled by climate change and relentless pressure on land and water resources, some of the most widespread and damaging drought events in recorded history have taken place since 2023, according to a UN-backed report launched today. Prepared by the U.S. National Drought Mitigation Center (NDMC) and the UN Convention to Combat Desertification (UNCCD), with support from the International Drought Resilience Alliance (IDRA), the report, "Drought Hotspots Around the World 2023-2025," provides a comprehensive account of how droughts compound poverty, ...

Study: To battle tip fatigue, businesses should make their service efforts visible

2025-07-02
PULLMAN, Wash. -- As customers face more and more prompts to add a tip to the bill in places where gratuities were not customary only a few years ago—and often before any service has been rendered—their attitudes toward the practice have turned sharply negative. “Businesses should seriously consider whether they want to offer that tipping request,” said Ruiying Cai, an assistant professor in the WSU’s Carson College of Business and co-author of a new study published in the International Journal of Hospitality ...

This spongy material and the sun’s power remove salt from seawater

2025-07-02
Most of Earth’s water is in the oceans and too salty to drink. Desalination plants can make seawater drinkable, but they require large amounts of energy. Now, researchers reporting in ACS Energy Letters have developed a sponge-like material with long, microscopic air pockets that uses sunlight and a simple plastic cover to turn saltwater into freshwater. A proof-of-concept test outdoors successfully produced potable water in natural sunlight in a step toward low-energy, sustainable desalination. This isn’t the first time scientists have created spongy materials that use sunlight as ...

Nearly 1 in 6 older adults take aspirin despite no history of heart disease

2025-07-02
Around 1 in 6 older adults take aspirin as their primary method of preventing cardiovascular disease – despite stricter guidelines that no longer always call for it, a study finds.   Almost one-quarter of those aspirin users started taking the medication without a physician recommendation and 8% had not discussed their use with any health care provider.   The results, published in the Journal of the American College of Cardiology, come from a survey of more than 2,500 adults aged ...

ACMG takes action to address national gap in newborn screening leadership

2025-07-02
BETHESDA, MD – July 2, 2025 | In response to the continued need for evidence-based reviews of newborn screening (NBS) conditions following the recent dissolution of the Advisory Committee on Heritable Disorders in Newborns and Children (ACHDNC), the American College of Medical Genetics and Genomics (ACMG) is moving forward with organizing a new advisory framework to uphold the integrity and scientific rigor of nationally coordinated NBS recommendations. To initiate this process, the ACMG will convene a virtual stakeholder roundtable this summer to gather ...

Stopping pancreatic cancer spread using benzaldehyde

2025-07-02
Cancer cells have the capacity to multiply rapidly. The aggressive cancer cells undergo conversion from their tightly connected epithelial state into a mesenchymal state, which lacks contact restrictions and spreads easily to other parts of the body. Such epithelial-to-mesenchymal plasticity also makes the cancer cells resistant to elimination by anticancer therapies. The search is ongoing for newer anticancer agents that can overcome this acquired resistance to therapy and destroy the ‘rogue’ cancer cells. A group of researchers led by Dr. Hideyuki Saya, Director of the Oncology Innovation Center, Fujita Health University, ...

Pusan National University study reveals engineered bacterial vesicles to combat antimicrobial resistance

2025-07-02
Bacteria are ubiquitous microscopic organisms capable of rapid growth. While beneficial strains like lactic acid bacteria (LAB) promote gut health and food preservation, pathogenic bacteria such as Escherichia coli and Staphylococcus aureus can cause severe infections. These harmful microbes produce toxins and enzymes that compromise health and, increasingly, show resistance to conventional antibiotics. In recent years, scientists have explored alternative approaches to tackle pathogenic bacteria. Among them, endolysins—enzymes that degrade bacterial cell walls—have emerged as potent tools. These proteins, often derived from bacteriophages or engineered microbes, offer ...

Africa needs more large firms, not more entrepreneurs, for economic growth

2025-07-02
Many experts suggest using the entrepreneurial ecosystems (EE) approach to help grow Africa’s economy, especially in poorer countries. EE looks at how things like roads, money, rules, and skilled people can come together to support business growth. But Africa already has more entrepreneurs than anywhere else—mostly people working for themselves because they have no other choice. This raises an important question: Is encouraging even more entrepreneurship really the best path for Africa’s growth? To gain more insights, ...

Clues in the claws: finger length may reveal sexual preferences in rats

2025-07-02
Sexual behavior and sex preference in animals and humans are shaped by complex interactions between the brain and hormones during early development. One critical factor is exposure to androgens (male sex hormones) during fetal development, which influences the sexual differentiation of the brain. This early hormonal exposure is linked to a wide range of adult behaviors, like sexual behavior and cognitive traits, but finding a reliable, non-invasive biological marker for the same has remained a challenge.   Now, a team of researchers led by Professor Hirotaka Sakamoto, along with Dr. Himeka Hayashi from Okayama University, ...

World-unique method enables simulation of error-correctable quantum computers

2025-07-02
Quantum computers still face a major hurdle on their pathway to practical use cases: their limited ability to correct the arising computational errors. To develop truly reliable quantum computers, researchers must be able to simulate quantum computations using conventional computers to verify their correctness – a vital yet extraordinarily difficult task. Now, in a world-first, researchers from Chalmers University of Technology in Sweden, the University of Milan, the University of Granada, and the University of Tokyo have unveiled a method for simulating ...

LAST 30 PRESS RELEASES:

Vaccination support program reduces pneumonia-related mortality by 25 percent among the elderly

Over decades, a healthy lifestyle outperforms metformin in preventing onset of Type 2 diabetes

Mental health disorders, malaria, and heart disease most affected by covid pandemic

Green transition will boost UK productivity

Billions voted in 2024, but major new report exposes cracks in global democracy

Researchers find “forever chemicals” impact the developing male brain

Quantum leap in precision sensing across technologies

Upgrading biocrude oil into sustainable aviation fuel using zeolite-supported iron-molybdenum carbide nanocatalysts

For effective science communication, ‘just the facts’ isn’t good enough

RT-EZ: A golden gate assembly toolkit for streamlined genetic engineering of rhodotorula toruloides

Stem Cell Reports announces five new early career editors

Support networks may be the missing link for college students who seek help for excessive drinking

The New England Journal of Medicine shines spotlight on forensic pathology

Scientists discover protein that helps lung cancer spread to the brain

Perceived social status tied to cardiovascular risks in women but not in men

Brain tumor growth patterns may help inform patient care management

This might be America's first campus tree inventory

Emoji use may impact relationship outcomes

Individual merit, not solidarity, prioritized by early childhood education policies

Preclinical study unlocks a mystery of rapid mouth healing

Extraterrestrial habitats: bioplastics for life beyond earth

U.S. military spending reductions could substantially lower energy consumption

Air pollution is linked to adverse birth outcomes in India

Using viral load tests to help predict mpox severity when skin lesions first appear

Engineered cell cross-talk unlocks CAR-T potential against glioblastoma

Regional disparities in US media coverage of archaeology research

Coral larvae travelling further makes populations stronger

First of its kind study for children with arthritis reveals possible new disease targets

Financing innovation: proposal for novel adaptive platform trial fund offers new model for ALS drug development

Disparities in treatment and referral after an opioid overdose among emergency department patients

[Press-News.org] Forging a novel therapeutic path for patients with Rett Syndrome using AI
AI-enabled drug discovery approach identified potentially game-changing treatment which has been advanced from the lab bench to an FDA Orphan Drug Designation in record time